Skip to main content
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. — Investor Relations & Filings

Ticker · WHWK ISIN · US00032Q1040 LEI · 549300G3U7TKW1M58L09 US Professional, scientific and technical activities
Open in API
Filings indexed 516 across all filing types
Latest filing 2017-07-31 Regulatory Filings
Country US United States of America
Listing US WHWK

About Whitehawk Therapeutics, Inc.

https://ir.whitehawktx.com/

Whitehawk Therapeutics, Inc. is a preclinical-stage oncology company focused on developing advanced antibody-drug conjugate (ADC) therapies. The company applies next-wave platform technologies to established tumor biology to create treatments for difficult-to-treat cancers. Its portfolio features three ADC assets, which are engineered to overcome the limitations of first-generation predecessors through improved tumor targeting and clinical strategies. These assets are in-licensed from WuXi Biologics under an exclusive agreement for global development and commercialization.

Recent filings

Filing Released Lang Actions
424B3 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, as indicated by the header and the text. It includes a description of a clinical study and other company events but does not contain comprehensive financial statements or detailed financial analysis. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). The document is a regulatory filing reporting a specific event (clinical study results) and is filed pursuant to the Securities Exchange Act of 1934. It is not a report publication announcement or a proxy statement. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6541 characters) supports that it is a substantive filing but not a full financial report.
2017-07-31 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the completion of a clinical study and its results, which is an 'Other Events' disclosure under Item 8.01. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, governance, or management change announcement. It is a regulatory filing reporting a material event outside the regular reporting schedule. The document length is 3765 characters, which is relatively short and consistent with a Form 8-K current report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-07-31 English
424B3 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed pursuant to the Securities Exchange Act of 1934, dated June 29, 2017. It includes a prospectus supplement related to a share offering and a press release announcing the initiation of patient dosing in a Phase 2b clinical trial. The content focuses on a specific event (clinical trial initiation) and a securities offering update, not on financial results or management discussion. There are no financial statements or detailed financial analysis present. The document is primarily an event announcement and a securities offering supplement, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update (CAP) because it is a prospectus supplement and current report, or Earnings Release (ER) or Annual Report (10-K). The length is over 5,000 characters, so it is not a mere report publication announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2017-06-29 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text includes an announcement of the initiation of patient dosing in a clinical trial and references a press release attached as an exhibit. There are no financial statements or detailed financial data presented. The document length is 2964 characters, which is relatively short and primarily serves as an announcement of an event rather than a detailed financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-06-29 English
424B3 Filing
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus related to the offering and resale of common stock by selling stockholders. It includes sections such as 'Prospectus Summary', 'Risk Factors', 'Management's Discussion and Analysis of Financial Condition and Results of Operations', 'Directors and Executive Officers', 'Executive Compensation', 'Selling Stockholders', 'Plan of Distribution', and 'Description of Capital Stock'. The document is filed pursuant to Rule 424(b)(3), which is a registration statement prospectus supplement used in securities offerings. The content focuses on the offering details, business overview, financial data, and stockholder information, which are typical of a capital raising or financing document. There is no indication that this is an annual report, earnings release, or other financial report. Instead, it is a registration prospectus related to a capital market transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2017-06-26 English
S-1/A Filing
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering. It includes detailed information about the company, the securities being offered, risk factors, management discussion, and other disclosures typical of a prospectus for an initial public offering or secondary offering. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to financing and securities registration. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, confirming it is not merely an announcement but the actual registration statement/prospectus.
2017-06-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.